Feasibility, Safety, and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastasis: A Registry Study

Table 1

Patient characteristics.

Variable	Value
Number of patients	71
Sex (M : F)	28 : 43
Age, years (±SD)	58 ± 13
Organ of origin
(i) Gastric	26 (36.6%)
(ii) Colorectal	17 (23.9%)
(iii) Hepatobiliary-pancreatic	9 (12.7%)
(iv) Ovarian	6 (8.5%)
(v) Appendiceal	5 (7.0%)
(vi) PMP	4 (5.6%)
(vii) CUP, mesothelioma, yolk sac, prostate	3 (4.2%)
Extraperitoneal metastasis
(i) Malignant pleural effusion	3 (4.2%)
(ii) Others	0
Peritoneal Cancer Index (PCI), mean ± SD	19.3 ± 12.5
Karnofsky Index before first PIPAC, mean ± SD	80.3 ± 14.7
Previous surgery
(i) CRS and HIPEC	10 (14.1%)
(ii) Gastrectomy	11 (15.5%)
(iii) Colectomy	11 (15.5%)
(iv) Hysterectomy and adnexectomy	5 (7.0%)
(v) Laparotomy	9 (12.7%)
(vi) Laparoscopy	4 (5.6%)
(vii) Other surgeries	14 (19.7%)
(viii) None	7 (9.9%)
Previous systemic chemotherapy
(i) None	11 (15.5%)
(ii) 1 line	18 (25.4%)
(iii) 2 lines	17 (23.9%)
(iv) 3 lines	10 (14.1%)
(v) >3 lines	15 (21.1%)
Simultaneous chemotherapy	42 (59.1%)